X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PLETHICO PHARMA ALEMBIC PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 26.6 -1.1 - View Chart
P/BV x 6.1 0.0 36,227.2% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ALEMBIC PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
PLETHICO PHARMA
Mar-14
ALEMBIC PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs792395 200.5%   
Low Rs44331 1,415.3%   
Sales per share (Unadj.) Rs167.0604.4 27.6%  
Earnings per share (Unadj.) Rs38.232.5 117.5%  
Cash flow per share (Unadj.) Rs42.051.3 81.8%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.9473.6 17.9%  
Shares outstanding (eoy) m188.5234.08 553.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.70.4 1,048.3%   
Avg P/E ratio x16.26.6 246.6%  
P/CF ratio (eoy) x14.74.2 354.1%  
Price / Book Value ratio x7.30.5 1,615.9%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3837,262 1,602.5%   
No. of employees `000NANA-   
Total wages/salary Rs m4,2141,596 264.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,48720,598 152.9%  
Other income Rs m55386 14.3%   
Total revenues Rs m31,54220,984 150.3%   
Gross profit Rs m10,0602,818 357.0%  
Depreciation Rs m722642 112.4%   
Interest Rs m371,593 2.3%   
Profit before tax Rs m9,356969 966.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160-138 -1,561.1%   
Profit after tax Rs m7,1941,107 650.0%  
Gross profit margin %31.913.7 233.6%  
Effective tax rate %23.1-14.3 -161.6%   
Net profit margin %22.85.4 425.2%  
BALANCE SHEET DATA
Current assets Rs m15,06618,877 79.8%   
Current liabilities Rs m7,67411,896 64.5%   
Net working cap to sales %23.533.9 69.3%  
Current ratio x2.01.6 123.7%  
Inventory Days Days6736 186.3%  
Debtors Days Days41198 20.5%  
Net fixed assets Rs m8,2379,861 83.5%   
Share capital Rs m377341 110.7%   
"Free" reserves Rs m15,41612,331 125.0%   
Net worth Rs m16,00516,139 99.2%   
Long term debt Rs m04,706 0.0%   
Total assets Rs m24,59433,146 74.2%  
Interest coverage x255.21.6 15,874.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.6 206.0%   
Return on assets %29.48.1 360.9%  
Return on equity %44.96.9 655.4%  
Return on capital %58.712.3 477.4%  
Exports to sales %55.721.4 260.8%   
Imports to sales %10.415.2 68.5%   
Exports (fob) Rs m17,5514,402 398.7%   
Imports (cif) Rs m3,2833,136 104.7%   
Fx inflow Rs m17,8114,402 404.6%   
Fx outflow Rs m5,3183,184 167.0%   
Net fx Rs m12,4931,219 1,025.2%   
CASH FLOW
From Operations Rs m9,3042,437 381.7%  
From Investments Rs m-3,105-6,265 49.6%  
From Financial Activity Rs m-1,9592,490 -78.7%  
Net Cashflow Rs m4,240-1,337 -317.1%  

Share Holding

Indian Promoters % 74.1 82.7 89.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 4.3 67.4%  
FIIs % 9.1 5.5 165.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 7.5 185.3%  
Shareholders   49,328 10,665 462.5%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   TORRENT PHARMA  NATCO PHARMA  ELDER PHARMA  PFIZER  ALKEM LABORATORIES  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS